Deep in the Colombian Amazon region of Serrania De La Lindosa, a roughly 12-mile stretch of rock is covered in a vast ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Wedbush restated their outperform rating on shares of Scholar Rock (NASDAQ:SRRK – Free Report) in a research note published on Wednesday,RTT News reports. They currently have a $47.00 target price on ...

Scholar Rock is asking the U.S. Food and Drug Administration to approve apitegromab for people with spinal muscular atrophy.

After years in the wilderness, Kenyan bands like Irony Destroyed, Last Year’s Tragedy and Rash are clawing their way up the ...

From Russia with love — of knowledge. A Long Island student who came to Mastic Beach as a child while knowing very little of ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has appointed Lisa Wyman as the Chief Technical and Quality Officer (CTQO) to support the company's growth and evolution. Wyman ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

Exchange Traded Concepts LLC lessened its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 81.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 18,887 shares ...

Scholar Rock (SRRK), a late-stage biopharmaceutical company developing innovative treatments for spinal muscular atrophy, ...

CAMBRIDGE, MA—Ho Junlin, General Counsel of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold 9,039 shares of the company's common stock. The shares were sold at an average price of $44. ...